Preoperative neutrophil-to-lymphocyte ratio is an independent prognostic marker in patients with laryngeal squamous cell carcinoma

Abstract

BackgroundNeutrophil-lymphocyte ratio (NLR) has been shown to be associated with prognosis in various solid tumors. This study aimed to evaluate the prognostic role of NLR in patients with laryngeal squamous cell carcinoma (LSCC).MethodsA total of 141 LSCC patients were retrospectively reviewed. Patients’ demographics were analyzed along with clinical and pathologic data. The optimal cutoff value of NLR was determined using receiver operating characteristic (ROC) curve analysis. The impact of the NLR and other potential prognostic factors on disease-free survival (DFS) and overall survival (OS) was assessed using the Kaplan-Meier method and multivariate Cox regression analysis.ResultsThe optimal cutoff value of the NLR was 2.17. In the NLR ≤ 2.17 group, the 1-, 3-, and 5-year DFS rates were 88.2, 73.9 and 69.1 %, respectively, while in the NLR > 2.17 group, the DFS rates were 83.0, 54.6 and 49.2 %, respectively. Correspondingly, the 1-, 3-, and 5-year OS rates were 98.9, 85.1 and 77.4 % in the NLR ≤ 2.17 group and 97.9, 63.8 and 53.3 % in the NLR > 2.17 group, respectively. The multivariate Cox proportional hazard model analysis showed that NLR > 2.17 was a prognostic factor for both DFS [hazard ratio (HR) = 1.869; 95 % confidence interval (CI) 1.078–3.243; P = 0.026] and OS (HR =2.177; 95 % CI 1.208–3.924; P = 0.010).ConclusionOur results showed that elevated preoperative NLR was an independent predictor of poor prognosis for patients with LSCC after surgical resection.

Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in malignant and precancerous laryngeal lesions

“…Kum et al [13] found statistical significance between the NLR values and the groups in the study conducted with 209 patients by studying three groups of benign, premalignant, and malignant lesions. In their study of 141 patients, Tu et al [14] found that elevated preoperative NLR was an independent predictor for poor prognosis after surgical resection in patients with LSCC. Gong et al [15] studied 161 patients and found that increased preoperative NLR could contribute to the advanced tumor node metastasis stage of papillary thyroid carcinoma in patients who were older than 45 years.…”

“…[13,14] To the best of our knowledge, this is the first study to suggest that PLR maybe used for PLL and LSCC discrimination. According to the current results PLR may be used for PLL and LSCC discrimination.…”

The prognostic value of systemic and local inflammation in patients with laryngeal squamous cell carcinoma

“…Laryngeal squamous cell carcinoma (LSCC) is one of the most common malignancies that remains as a significant cause of morbidity and mortality in head and neck 1. It is estimated that the new cases of laryngeal cancer expected among men and women in China in 2015 are 23,700 and 2,600, respectively; and the estimated number of deaths from laryngeal cancer is about 14,500 2.…”

“…Cumulating evidence suggests that increased systemic inflammation might represent a stage-independent unfavorable prognostic factor in different types of cancer 1,12–15. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), which reflect the systemic inflammation, are readily available and effective predictors of poor survival outcome across various cancers, including intrahepatic cholangiocarcinoma,12 breast cancer,13 colorectal cancer,14 LSCC,1,15 and so on.…”

“…Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), which reflect the systemic inflammation, are readily available and effective predictors of poor survival outcome across various cancers, including intrahepatic cholangiocarcinoma,12 breast cancer,13 colorectal cancer,14 LSCC,1,15 and so on. In contrast, a high density of tumor infiltrating lymphocytes (TILs), which represents a robust intratumoral inflammatory response, is recognized as a good prognostic marker in multiple malignancies, such as breast cancer,16 colon cancer,17 and gastric cancer 18.…”